Abstract
Objective
The purpose of this study was developing the new delivery system of antisense HIF1α oligodeoxynucleotide (ASO) into the stiff adipocytes. As the adipogenesis progressed, accumulating lipid droplet in cytosol lead adipocytes membrane stiffness and difficulties in the delivery of therapeutic agents into the cytosol. Hypoxia affects a number of biological functions including angiogenesis, apoptosis, inflammation, and adipogenesis. Hypoxia-inducible transcription factor-1 alpha (HIF1α) is a major transcription factor that controls metabolic and adipogenic gene expression under hypoxia. Controlling HIFα expression can be a promising therapy for obesity treatment.
Methods
The ASO was synthesized and used in a complex with polylactic-co-glycolic acid (PLGA) nanoparticles (NP). To enhance the cell-penetrating capacity, the PLGA-ASO-NP complex was coated with arginine-rich peptide (ARP) in different N:P molar ratios (PLGA-ASO-NP:ARP = 1: 1, 2: 1, 5: 1). To examine the intracellular and intranuclear delivery, these complexes were treated to fully differentiated adipocyte.
Results
The PLGA-ASO-NP/ARP improved the efficacy of ASO-delivery into stiff adipocytes by increasing the cell surface charge, determined by the zeta potential, and forming polyplexes with small particle size. The proper N:P molar ratio of PLGA-ASO-NP/ARP synthesis was 5:1 with significantly improved gene delivery efficiency and intracellular uptake in adipocytes. Furthermore, PLGA-ASO-NP/ARP was stable in serum for 8 h compared to naked ASO.
Conclusion
These results suggest that the PLGA-ASO-NP/ARP can provide an effective and serum-stable gene-delivery system, especially for cells with a stiff cell membrane.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barness, L. A., Opitz, J. M. & Gilbert-Barness, E. Obesity: genetic, molecular, and environmental aspects. Am. J. Med. Genet. A. 143A, 3016–3034 (2007).
Hjartaker, A., Langseth, H. & Weiderpass, E. Obesity and diabetes epidemics: cancer repercussions. Adv. Exp. Med. Biol. 630, 72–93 (2008).
Zhu, Y. et al. A novel type of self-assembled nanoparticles as targeted gene carriers: an application for plasmid DNA and antimicroRNA oligonucleotide delivery. Int. J. Nanomedicine 11, 399–410 (2016).
Mykhaylyk, O. et al. Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro. Methods. Mol. Biol. 1218, 53–106 (2015).
Le, T. D., Nakagawa, O., Fisher, M., Juliano, R. L. & Yoo, H. RGD Conjugated Dendritic Polylysine for Cellular Delivery of Antisense Oligonucleotide. J. Nanoc. 17, 2353–2357 (2017).
Jabs, D. A. & Griffiths, P. D. Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol. 133, 552–556 (2002).
Shoham, N. et al. Adipocyte stiffness increases with accumulation of lipid droplets. Biophys. J. 106, 1421–1431 (2014).
Zhang, C. & Liu, P. The lipid droplet: A conserved cellular organelle. Protein & Cell 8, 796–800 (2017).
Garcia-Chaumont, C., Seksek, O., Grzybowska, J., Borowski, E. & Bolard, J. Delivery systems for antisense oligonucleotides. Pharmacol. Ther. 87, 255–277 (2000).
Gao, J. Q. et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control. Release. 122, 102–110 (2007).
Park, K. Non-ionic polymersomes for delivery of oligonucleotides. J. Control. Release. 134, 73 (2009).
Kim, Y. et al. Polymersome delivery of siRNA and antisense oligonucleotides. J. Control. Release. 134, 132–140 (2009).
McClorey, G. & Banerjee, S. Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics. Biomedicines 6 (2018).
Astriab-Fisher, A., Sergueev, D., Fisher, M., Shaw, B. R. & Juliano, R. L. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm. Res. 19, 744–754 (2002).
Dong, L. et al. Targeting delivery oligonucleotide into macrophages by cationic polysaccharide from Bletilla striata successfully inhibited the expression of TNF-alpha. J. Control. Release. 134, 214–220 (2009).
Fisher, A. A. et al. Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J. Biol. Chem. 277, 22980–22984 (2002).
Luten, J., van Nostrum, C. F., De Smedt, S. C. & Hennink, W. E. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release. 126, 97–110 (2008).
Ropelle, E. R. et al. Inhibition of hypothalamic Foxo1 expression reduced food intake in diet-induced obesity rats. J. Phtsiol. 587, 2341–2351 (2009).
Langhi, C. et al. Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance. J. Lipid. Res. 58, 81–91 (2017).
Cao, Y. et al. Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment. Sci. Rep. 7, 9307 (2017).
Crooke, R. M. et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid. Res. 46, 872–884 (2005).
Helsley, R. N. et al. Targeting IkappaB kinase beta in Adipocyte Lineage Cells for Treatment of Obesity and Metabolic Dysfunctions. Stem Cells 34, 1883–1895 (2016).
Yu, X. X. et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS One 8, e66923 (2013).
Popov, V. B. et al. Second-generation antisense oligonucleotides against beta-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance. FASEB. J. 30, 1207–1217 (2016).
Watts, L. M. et al. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54, 1846–1853 (2005).
Vitto, M. F. et al. Reversion of steatosis by SREBP-1c antisense oligonucleotide did not improve hepatic insulin action in diet-induced obesity mice. Horm. Metab. Res. 44, 885–890 (2012).
Park, Y. S. et al. Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide. J. Control. Release. 144, 82–90 (2010).
Takashima, Y. et al. Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. Int. J. Pharm. 343, 262–269 (2007).
Kolte, A., Patil, S., Lesimple, P., Hanrahan, J. W. & Misra, A. PEGylated composite nanoparticles of PLGA and polyethylenimine for safe and efficient delivery of pDNA to lungs. Int. J. Pharm. 524, 382–396 (2017).
Hosogai, N. et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901–911 (2007).
Fleischmann, E. et al. Tissue oxygenation in obese and non-obese patients during laparoscopy. Obes. Surg. 15, 813–819 (2005).
Malcolm, D. W., Varghese, J. J., Sorrells, J. E., Ovitt, C. E. & Benoit, D. S. W. The Effects of Biological Fluids on Colloidal Stability and siRNA Delivery of a pH-Responsive Micellar Nanoparticle Delivery System. ACS. nano. 12, 187–197 (2018).
Yang, C. et al. Theranostic poly (lactic-co-glycolic acid) nanoparticle for magnetic resonance/infrared fluorescence bimodal imaging and efficient siRNA delivery to macrophages and its evaluation in a kidney injury model. Nanomedicine 13, 2451–2462 (2017).
Brock, R. The uptake of arginine-rich cell-penetrating peptides: putting the puzzle together. Bioconjug. Chem. 25, 863–868 (2014).
Park, Y. J. et al. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB. J. 19, 1555–1557 (2005).
Li, Y. T. et al. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J. Biomed. Mater. Res. A. 91, 209–220 (2009).
Ahn, S., Seo, E., Kim, K. & Lee, S. J. Controlled cellular uptake and drug efficacy of nanotherapeutics. Sci. Rep. 3, 1997 (2013).
Cho, E. C., Xie, J., Wurm, P. A. & Xia, Y. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Letters 9, 1080–1084 (2009).
Pindiprolu, S., Chintamaneni, P. K., Krishnamurthy, P. T. & Ratna Sree Ganapathineedi, K. Formulation-optimization of solid lipid nanocarrier system of STAT3 inhibitor to improve its activity in triple negative breast cancer cells. Drug Dev. Ind. Pharm. 1–10 (2018).
dos Santos, T., Varela, J., Lynch, I., Salvati, A. & Dawson, K. A. Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small 7, 3341–3349 (2011).
Harush-Frenkel, O., Debotton, N., Benita, S. & Altschuler, Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353, 26–32 (2007).
Verma, A. & Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small 6, 12–21 (2010).
Midoux, P. & Monsigny, M. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug. Chem. 10, 406–411 (1999).
Junghans, M., Kreuter, J. & Zimmer, A. Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res. 28, E45 (2000).
Harush-Frenkel, O., Rozentur, E., Benita, S. & Altschuler, Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9, 435–443 (2008).
Cu, Y., LeMoellic, C., Caplan, M. J. & Saltzman, W. M. Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency. Nanomedicine 6, 334–343 (2010).
Verma, A. et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 7, 588–595 (2008).
Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848–866 (2007).
Park, Y. S. et al. Controlled release of simvastatin from in situ forming hydrogel triggers bone formation in MC3T3-E1 cells. AAPS. J. 15, 367–376 (2013).
Acknowledgements
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2017R1A2B4002611), and partly by the Technological innovation R&D program of SMBA (S2449311).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, D.H., Park, Y.S. Arginine-rich Peptide Coated PLGA Nanoparticles Enhance Polymeric Delivery of Antisense HIF1α-oligonucleotide to Fully Differentiated Stiff Adipocytes. Toxicol. Environ. Health Sci. 11, 1–10 (2019). https://doi.org/10.1007/s13530-019-0382-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13530-019-0382-8